Literature DB >> 27144220

Tumefactive brain lesion with rapid cavity formation associated with anti-aquaporin-4 antibody.

Takuya Uehara1, Goichi Beck1, Kousuke Baba1, Masahito Mihara1, Tatsusada Okuno1, Hisae Sumi1, Yuji Nakatsuji1, Hideki Mochizuki1.   

Abstract

Entities:  

Year:  2016        PMID: 27144220      PMCID: PMC4841638          DOI: 10.1212/NXI.0000000000000230

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
A 54-year-old woman with no medical history presented with left hemiparesis and hemianopsia. Brain MRI showed an extensive lesion without enhancement in the right parietal lobe, followed by rapid cavity formation (figure 1). Brain biopsy performed 55 days after disease onset revealed decreased glial fibrillary acidic protein and aquaporin-4 (AQP4) immunoreactivity, though we could not show the activated complement due to the paucity of the sample (figure 2).
Figure 1

MRI of the brain

Noncontrast fluid-attenuated inversion recovery images on days 2 (A), 8 (B), and 35 (C). Note extensive cavity formation on day 35. The lesion shows high intensity on an apparent diffusion coefficient map on day 2 (D). Enhanced T1-weighted images on days 3 (E) and 35 (F) show no enhancement.

Figure 2

Brain biopsy

(A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of AQP4 immunoreactivity with myelin pallor is shown (surrounded by arrows). (B) Staining with glial fibrillary acidic protein (GFAP) (brown) is shown. Loss of GFAP immunoreactivity is observed in the corresponding area shown in A (surrounded by arrows). Scale bar: 50 μm.

MRI of the brain

Noncontrast fluid-attenuated inversion recovery images on days 2 (A), 8 (B), and 35 (C). Note extensive cavity formation on day 35. The lesion shows high intensity on an apparent diffusion coefficient map on day 2 (D). Enhanced T1-weighted images on days 3 (E) and 35 (F) show no enhancement.

Brain biopsy

(A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of AQP4 immunoreactivity with myelin pallor is shown (surrounded by arrows). (B) Staining with glial fibrillary acidic protein (GFAP) (brown) is shown. Loss of GFAP immunoreactivity is observed in the corresponding area shown in A (surrounded by arrows). Scale bar: 50 μm. Brain biopsy results revealed that the patient was positive for anti-AQP4 antibody. She received methylprednisolone pulse therapy, followed by plasmapheresis. Progression was inhibited. Based on anti-AQP4 antibody-seropositive cases, the concept of neuromyelitis optica spectrum disorders is becoming broader.[1] These disorders should be considered in differential diagnoses when tumefactive brain lesions are observed.[2] Our case highlights the importance of examining AQP4 immunoglobulin G, because it could result in an early diagnosis without performing biopsy.[3]
  3 in total

1.  Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder.

Authors:  Woojun Kim; Su-Hyun Kim; Sang Hyun Lee; Xue Feng Li; Ho Jin Kim
Journal:  Mult Scler       Date:  2011-05-04       Impact factor: 6.312

2.  Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.

Authors:  Bogdan F G Popescu; Yong Guo; Mark E Jentoft; Joseph E Parisi; Vanda A Lennon; Sean J Pittock; Brian G Weinshenker; Dean M Wingerchuk; Caterina Giannini; Imke Metz; Wolfgang Brück; Elizabeth A Shuster; Jonathan Carter; Clara D Boyd; Stacey Lynn Clardy; Bruce A Cohen; Claudia F Lucchinetti
Journal:  Neurology       Date:  2014-12-10       Impact factor: 9.910

3.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.